Metformin Blocks Migration and Invasion of Tumour Cells by Inhibition of Matrix Metalloproteinase-9 Activation Through a Calcium and Protein Kinase Calpha-dependent Pathway: Phorbol-12-myristate-13-acetate-induced/extracellular Signal-regulated...

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2010 Jul 2

PMID 20590612

Citations 51

Authors

Yong P Hwang

Hye G Jeong

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Population studies have revealed that treatment with the anti-diabetic drug metformin is significantly associated with reduced cancer risk, but the underlying mode of action has not been elucidated. The aim of our study was to determine the effect of metformin on tumour invasion and migration, and the possible mechanisms, using human fibrosarcoma HT-1080 cells.

Experimental Approach: We employed invasion, migration and gelatin zymography assays to characterize the effect of metformin on HT-1080 cells. Transient transfection assays were performed to gene promoter activities, and immunoblot analysis to study its molecular mechanisms of action.

Key Results: Metformin inhibited migration and invasion by HT-1080 cells at sub-toxic concentrations. In these cells, metformin also suppressed phorbol-12-myristate-13-acetate (PMA)-enhanced levels of matrix metalloproteinases-9 (MMP-9) protein, mRNA and transcription activity through suppression of activator protein-1 (AP-1) activation. In addition, metformin strongly repressed the PMA-induced phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and protein kinase C(PKC)alpha, whereas the phosphorylation of p38 mitogen-activated protein kinase was not affected by metformin. Metformin decreased the PMA-induced Ca(2+) influx. Furthermore, treatment with an intracellular Ca(2+) chelator (BAPTA-AM) or a selective calmodulin antagonist (W7) markedly decreased PMA-induced MMP-9 secretion and cell migration, as well as activation of ERK and JNK/AP-1.

Conclusions And Implications: Metformin inhibited PMA-induced invasion and migration of human fibrosarcoma cells via Ca(2+)-dependent PKCalpha/ERK and JNK/AP-1-signalling pathways. Metformin therefore has the potential to be a potent anti-cancer drug in therapeutic strategies for fibrosarcoma metastasis.

Citing Articles

Metformin as a Potential Therapeutic Agent in Breast Cancer: Targeting miR-125a Methylation and Epigenetic Regulation.

Ahmadpour F, Igder S, Eftekhari Moghadam A, Moradipoodeh B, Sepahdar A, Mokarram P Int J Mol Cell Med. 2024; 13(3):272-285.

PMID: 39493516 PMC: 11530948. DOI: 10.22088/IJMCM.BUMS.13.3.272.

Exploring the link between metformin use and adhesive capsulitis of the shoulder: a retrospective cohort study in Taiwan.

Lin B, Chien W, Lu C, Chung C, Tsao C, Weng T Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9947-9963.

PMID: 38953970 DOI: 10.1007/s00210-024-03246-w.

Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer.

Conza D, Mirra P, Fiory F, Insabato L, Nicolo A, Beguinot F Cells. 2023; 12(17).

PMID: 37681914 PMC: 10486775. DOI: 10.3390/cells12172182.

Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma.

Hahn S, Oh B, Kim H, Han I, Shin S, Kim G Am J Cancer Res. 2023; 13(5):1806-1825.

PMID: 37293149 PMC: 10244103.

Synergistic Effects of Caffeine in Combination with Conventional Drugs: Perspectives of a Drug That Never Ages.

Ialongo D, Tudino V, Arpacioglu M, Messore A, Patacchini E, Costi R Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242514 PMC: 10224171. DOI: 10.3390/ph16050730.

References

Buys S, Keogh E, Kaplan J . Fusion of intracellular membrane pools with cell surfaces of macrophages stimulated by phorbol esters and calcium ionophores. Cell. 1984; 38(2):569-76. DOI: 10.1016/0092-8674(84)90511-7. View

Phoenix K, Vumbaca F, Claffey K . Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2008; 113(1):101-11. PMC: 2606917. DOI: 10.1007/s10549-008-9916-5. View

Soderling T . The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci. 1999; 24(6):232-6. DOI: 10.1016/s0968-0004(99)01383-3. View

Buzzai M, Jones R, Amaravadi R, Lum J, DeBerardinis R, Zhao F . Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007; 67(14):6745-52. DOI: 10.1158/0008-5472.CAN-06-4447. View

Sudbeck B, Pilcher B, Pentland A, Parks W . Modulation of intracellular calcium levels inhibits secretion of collagenase 1 by migrating keratinocytes. Mol Biol Cell. 1997; 8(5):811-24. PMC: 276131. DOI: 10.1091/mbc.8.5.811. View

Westermarck J, Kahari V . Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13(8):781-92. View

Kazes I, Elalamy I, Sraer J, Hatmi M, Nguyen G . Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000; 96(9):3064-9. View

Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V . Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007; 64(10):1290-302. PMC: 11136022. DOI: 10.1007/s00018-007-7080-4. View

Shim J, Lee J, Kim K, Kwon H . Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochem Biophys Res Commun. 2007; 359(3):747-51. DOI: 10.1016/j.bbrc.2007.05.174. View

10.

Schuller H, Correa E, Orloff M, Reznik G . Successful chemotherapy of experimental neuroendocrine lung tumors in hamsters with an antagonist of Ca2+/calmodulin. Cancer Res. 1990; 50(5):1645-9. View

11.

McCawley L, Matrisian L . Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000; 6(4):149-56. DOI: 10.1016/s1357-4310(00)01686-5. View

12.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

13.

Chin D, Means A . Mechanisms for regulation of calmodulin kinase IIalpha by Ca(2+)/calmodulin and autophosphorylation of threonine 286. Biochemistry. 2002; 41(47):14001-9. DOI: 10.1021/bi025640o. View

14.

Dominguez L, Davidoff A, Srinivas P, Standley P, Walsh M, Sowers J . Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology. 1996; 137(1):113-21. DOI: 10.1210/endo.137.1.8536601. View

15.

Kohn E, Jacobs W, Kim Y, Alessandro R, Stetler-Stevenson W, Liotta L . Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem. 1994; 269(34):21505-11. View

16.

Sharma R, Bhalla R . Metformin attenuates agonist-stimulated calcium transients in vascular smooth muscle cells. Clin Exp Hypertens. 1995; 17(6):913-29. DOI: 10.3109/10641969509033643. View

17.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

18.

Sato T, Koike L, Miyata Y, Hirata M, Mimaki Y, Sashida Y . Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of.... Cancer Res. 2002; 62(4):1025-9. View

19.

Schmidt H, Pollock J, Nakane M, Forstermann U, Murad F . Ca2+/calmodulin-regulated nitric oxide synthases. Cell Calcium. 1992; 13(6-7):427-34. DOI: 10.1016/0143-4160(92)90055-w. View

20.

Deryugina E, Luo G, Reisfeld R, Bourdon M, Strongin A . Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res. 1997; 17(5A):3201-10. View